SEC Form 4 · accession 0001209191-17-058481
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ian F Smith
Officer — EVP, COO
Period of report
Oct 31, 2017
Accepted (ET)
Oct 31, 2017 · 6:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Oct 31, 2017 | S | 1,700 | $142.40 | D | 114,188 | D | |
| Common StockF3,F4 | Oct 31, 2017 | S | 5,200 | $143.47 | D | 108,988 | D | |
| Common StockF3,F5 | Oct 31, 2017 | S | 32,945 | $144.47 | D | 76,043 | D | |
| Common StockF3,F6 | Oct 31, 2017 | S | 22,464 | $145.26 | D | 53,579 | D | |
| Common StockF3,F7 | Oct 31, 2017 | S | 5,200 | $146.39 | D | 48,379 | D | |
| Common StockF3,F8 | Oct 31, 2017 | S | 3,500 | $147.40 | D | 44,879 | D | |
| Common StockF3,F9 | Oct 31, 2017 | S | 3,791 | $148.26 | D | 41,088 | D | |
| Common Stock | Oct 31, 2017 | S | 200 | $149.34 | D | 40,888 | D | |
| Common Stock | holding | — | — | — | 5,306 | I | 401(k) |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to Mr. Smith's company-approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $142.40 (range $141.83 to $142.75).
- F3Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $143.47 (range $142.91 to $143.85).
- F5Open market sales reported on this line occurred at a weighted average price of $144.47 (range $143.91 to $144.89).
- F6Open market sales reported on this line occurred at a weighted average price of $145.26 (range $144.93 to $145.87).
- F7Open market sales reported on this line occurred at a weighted average price of $146.39 (range $145.30 to $146.92).
- F8Open market sales reported on this line occurred at a weighted average price of $147.40 (range $146.93 to $147.90).
- F9Open market sales reported on this line occurred at a weighted average price of $148.26 (range $147.93 to $148.70).